MORRIS BLOUNT: Open Payments
NPI 1003912601 · LYNWOOD, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$933 in 44 payments from 9 companies in 2025. Trend: 2023 $914 · 2024 $823 · 2025 $933
Food & beverage: $831Education: $101
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 12 | $250 |
| Teva Pharmaceuticals USA, Inc. | 8 | $195 |
| Neurocrine BioSciences, Inc. | 6 | $120 |
| Alkermes, Inc. | 6 | $115 |
| Janssen Pharmaceuticals, Inc | 3 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Vanda Pharmaceuticals Inc. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Lundbeck LLC | 1 | $14 |
Products named: COBENFY, INGREZZA, INVEGA SUSTENNA, FANAPT, ARISTADA, UZEDY, LYBALVI, REXULTI.
Industry payments across IL — which companies pay providers there.
